Stock Update (NASDAQ:MDVN): Medivation Inc Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area


Medivation Inc (NASDAQ:MDVN) announced that for the third year in a row it was named among the top mid-sized companies in the San Francisco Bay Area News Group’s annual Top Workplaces competition. The results of the employee survey were featured in the most recent Top Workplaces special edition published in the San Jose Mercury News, on Sunday, June 28th. Medivationwas ranked 31 among mid-sized companies and is the only biopharmaceutical company in that category.

“We are incredibly proud that our employees have placed Medivation among the best places to work for three years in a row in the booming San Francisco business community,” said David Hung, M.D., founder, president and chief executive officer at Medivation.

Dr. Hung added, “This recognition is a testament to the unique culture and passionate commitment we feel for our important work at Medivation. My colleagues carry this unique spirit across all we do, which has led to our impressive milestones and the continued drive to pursue the opportunities ahead. Now more than ever, Medivation is an exciting place to work and I am truly honored that our employees feel the same way.” (Original Source)

Shares of Medivation closed last Friday at $112.31 . MDVN has a 1-year high of $141.58 and a 1-year low of $69.11. The stock’s 50-day moving average is $120.50 and its 200-day moving average is $117.51.

On the ratings front, Medivation has been the subject of a number of recent research reports. In a report issued on June 4, Maxim Group analyst Jason Kolbert reiterated a Buy rating on MDVN, with a price target of $168, which represents a potential upside of 49.6% from where the stock is currently trading. Separately, on June 2, Brean Murray Carret’s Jonathan Aschoff maintained a Buy rating on the stock and has a price target of $142.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Jonathan Aschoff have a total average return of 1.5% and 11.1% respectively. Kolbert has a success rate of 42.0% and is ranked #1566 out of 3681 analysts, while Aschoff has a success rate of 53.8% and is ranked #232.

In total, 3 research analysts have assigned a Hold rating and 6 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $144.63 which is 28.8% above where the stock closed last Friday.

Medivation Inc is a biopharmaceutical company engaged in the development of novel small molecule drugs to treat diseases like Alzheimer’s disease and Huntington disease.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts